Last reviewed 2026-04-22 · How we verify

IPV-Al

IPV-Al is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes.

IPV-Al is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes. Used for Poliomyelitis prevention in infants, children, and adults.

At a glance

Mechanism of action

IPV-Al contains chemically inactivated (killed) poliovirus particles of types 1, 2, and 3, which are administered intramuscularly to induce humoral and cellular immune responses. This vaccination prevents infection by poliovirus and the development of poliomyelitis. The vaccine is adsorbed onto aluminum hydroxide adjuvant to enhance immunogenicity.

Approved indications

• Poliomyelitis prevention in infants, children, and adults

Common side effects

• Local injection site reactions (pain, redness, swelling)
• Fever
• Irritability or fussiness

Key clinical trials

• Virtual Village for Young Parents (NA)
• Empowering Young Parents: Building Healthy Relationships Study (NA)
• Cognitive Processing Therapy in Syrian Women Exposed to IPV (NA)
• Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®) (PHASE4)
• Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months (PHASE3)
• Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age (PHASE3)
• 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents (PHASE1, PHASE2)
• 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.